Treating COVID Spike Protein Related Illnesses

There are two primary therapeutic targets that must be addressed in treating COVID spike protein related illnesses such as Long COVID and Post-Vaccine Syndrome.
Watch the video : Long Covid Treatment – 5 Modalities that Work

Before we address questions regarding COVID Spike Protein illnesses, it is important to state that the science investigating these illnesses is still in the early stages of development. Simply stated, this kind of spike protein that is in itself highly toxic to human tissues independent of its role as part of the virus (the mechanism by which a corona virus attaches to a host cell), is new to medical science.

We are just beginning to understand all the ways this spike protein damages the various organ systems in the human body, and thus the list of symptoms that are associated with this spike protein, such as Long Haul COVID and serious systemic Injuries induced by the COVID vaccine, keeps getting longer. (Over 200 documented symptoms)

Explore the photos below to get an in-depth view of the modalities we use to treat COVIID related spike protein illnesses.

The Lab Tests Show Nothing is Wrong

What is particularly challenging and frustrating about evaluating patients who present with a grouping of multiple symptoms that may have never been previously documented as related to each other, is that there are no empirical laboratory tests that can objectively detect and determine the actual cause of why this patient is suffering from this particular group of symptoms.

If you are reading this article because you are one of these patients, then you probably already know this.

You have been really sick for way too long, and after seeing multiple doctors who ran all sorts of lab tests on you already, the lab tests typically show that nothing is wrong, and that you are “normal”, despite that fact that you feel terrible. The lab across the street says you are fine… but the lab you are living in – your body – says that “functionally”, you are sick as a dog.

Learning What Works from Our Patients – Functional Medicine

Therefore, from a clinical perspective, the best we can do for the wellbeing of our patients is to approach them (and you who are reading this) from the perspective of “Functional Medicine”.

  1. Describe what we know – so far – about how the spike protein causes all this damage to our organ systems,
  2. Explain to our patients the empirical facts about the protocols we use to treat our patients, and
  3. Explain the “clinical outcomes” of what we are learning from how our patients are responding to these protocols.

Thus, in all our educational outreach to our patients and to the public, we present all that we are learning from our own clinical research and from all that we are learning from information presented by other clinics, forums, seminars etc. who are doing the same.

Explore the photos below to get an in-depth view of the modalities we use to treat COVIID related spike protein illnesses.

Primary Targets in Treating Spike Protein Illness

In treating COVID spike protein related illnesses, even long after the virus itself is gone, such as Long Haul COVID and COVID vaccine injuries (Post-vaccine Syndrome), there are two primary therapeutic targets that must be addressed.

  1. The first target is clearing the body of the spike protein which is itself very toxic and is – as far as we can tell – the cause of the many symptoms generated in the various organs that the spike proteins infected.
  2. The second target is healing and repairing the various organs that were damaged by the spike proteins.

The Good News of Target #2:

Target #2: Having treated thousands of very sick patients (collectively) with Covid related illnesses, we know that the modalities we use and new modalities that we constantly add to the protocols are successfully healing organs damaged by the spike proteins. We know this from the obvious clinical outcomes of patients who are completely healed of all their spike protein related symptoms.

Again, this is achieved with a careful “functional” approach, wherein with careful, meticulous, ongoing observation and assessment of how each patient is responding to each of the modalities we use in our protocols, we continuously adjust the protocol to achieve the best possible response.
Watch the video : I’m No Longer the Long COVID Walking Dead

Bottom line, if we pay close enough attention, the patient’s own physiology will tell us what is working and direct how to administer our protocols. Our clinical statistics show that the vast majority – around 85% – are back to their normal life (Yay!) within 3-5 weeks of treatments.

A smaller minority – approximately 15% – are not as responsive as the majority group. We don’t know why, but these patients require additional treatments before we “figure them out” and help their physiology recover and bring them back up to the top of the vitality mountain.

Watch the video : I was Vaccine Injured. It was Terrifying. To be Completely Honest.

The Good and Not so Good News of Target #1:

Target #1: Here we have good news and not so good news. The good news is that our human physiology is designed with mechanisms of identifying, capturing, and removing foreign toxic elements that don’t belong, such as the spike proteins. Thus, if given enough time and support our immune system are designed to clear our bodies of the spike proteins.

The not so good news is that for those who received the mRNA vaccines, our bodies have been injected with the cellular programing of creating our own spike proteins. The obvious and scary question that now emerges for the first time in history is:

Are the toxic spike proteins made by our own cells recognized by our immune system as foreign?!

If our immune systems don’t recognize these self-made spike proteins as foreign, how will we ever get rid of them? The 2nd obvious and scary question is:

How long will our cells keep making the spike protein that was induced by the vaccine?

The unfortunate truth is that we don’t know the answers to either of these two scary questions.

Therefore, developing treatments that can clear our bodies of spike proteins is critically important, especially if our vaccine programmed cells continue to make spike protein for a long time. To this day, no such technology has been developed that is proven to remove the spike protein from our bodies.

Explore the photos below to get an in-depth view of the EBOO /F (apheresis) treatment used to treat COVID related spike protein illnesses and the “debris” that is removed from our patient’s blood.

Treatments that are Working

In the meantime, we have contracted reputable labs to analyze the contents of the filters used in apheresis (EBOO) treatments, and thus have proof that in addition to the functional improvement in symptoms, that EBOO treatments clean out our patients’ blood various toxic debris such as biofilm and a variety of obscure irregular clotting structures in patients suffering from COVID spike protein illnesses.

Apheresis may also be clearing spike protein out of our blood, but so far, lab technologies have not been able to definitively identify the presence of spike protein in blood.

PATIENT 1143 : The patient’s blood before and after treatment with the EBOO /F device. The photo on the left is before the treatment. The center photo is of a fiber inside the patient’s used dialyzer. The photo on the right is the patient’s blood immediately after the treatment.

Early Intervention ALWAYS Produces Superior Results

For those who are suffering from COVID vaccine injuries there is more good news.

Even in the case where we assume that their genetically reprogramed cells persist in making toxic spike proteins for extended periods of time. Should that be the case, and these patients experience a recurrence of spike protein symptoms at some point in the future, having already gone through the process once before, these patients can quickly identify the symptoms, and quickly attend to accessing protocols such as ours.

These protocols that have already proven successful in engaging with their physiology should work even better this time around because early intervention always produces superior results. Besides, our protocols, in collaboration with many colleagues, are bound to become more effective as the science advances.

The Pursuit of Robust Health, Vitality & Longevity

Finally, Unrelated to spike protein illnesses, it is important for everyone to know, that all the modalities that we use in our Integrative approach to COVID spike protein illnesses, and as described on our website and in our educational videos, are safe and healthy to use in the treatment of countless other conditions, including the wise pursuit of robust health, vitality, and longevity.

One example among countless others, we know that EBOO /F Apheresis is proven to assist patients in a variety of other important ways, such as those suffering from uncontrolled high levels of lipids in their blood as well as those suffering from heavy metal toxicity to name a select few examples.

Learn More About Our Treatments for COVID Illneses

Everything on our website comes from from reputable publications, books and scientific journals, most of which are available on PubMed and other government websites. These include Meta-Analysis’, Randomized Controlled Trials, Clinical Trials, Systematic Reviews, Books and Documents. We encourage you to read the science, in order to separate fact from fiction, so that you can arrive at a full understanding of what is best for your body. We would be honored to be a part of that educational journey with you.

  1. Raveendran AV, Jayadevan R, Sashidharan S. Long COVID: An overview. Diabetes Metab Syndr. 2021;15(3):869-875.
  2. Stefano GB, Ptacek R, Ptackova H, Martin A, Kream RM. Selective Neuronal Mitochondrial Targeting in SARS-CoV-2 Infection Affects Cognitive Processes to Induce ‘Brain Fog’ and Results in Behavioral Changes that Favor Viral Survival. Med Sci Monit. 2021 Jan 25;27:e930886. doi: 10.12659/MSM.930886. PMID: 33487628; PMCID: PMC7845145.
  3. Block T, Kuo J. Rationale for Nicotinamide Adenine Dinucleotide (NAD+) Metabolome Disruption as a Pathogenic Mechanism of Post-Acute COVID-19 Syndrome. Clin Pathol. 2022 Jun 24;15:2632010X221106986. doi: 10.1177/2632010X221106986. PMID: 35769168; PMCID: PMC9234841.
  4. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19. PLoS Med. 2021;18(9):e1003773. Published 2021 Sep 28.
  5. Lechuga GC, Souza-Silva F, Sacramento CQ, et al. SARS-CoV-2 Proteins Bind to Hemoglobin and Its Metabolites. Int J Mol Sci. 2021;22(16):9035. Published 2021 Aug 21. 
  6. liu wenzhong, li hualan. COVID-19: Attacks the 1-beta Chain of Hemoglobin to Disrupt Respiratory Function and Escape Immunity . ChemRxiv. Cambridge: Cambridge Open Engage; 2022; This content is a preprint and has not been peer-reviewed.
  7. Hannah E. Davis, Gina S. Assaf, Lisa McCorkell, Hannah Wei, Ryan J. Low, Yochai Re’em, Signe Redfield, Jared P. Austin, Athena Akrami, Characterizing long COVID in an international cohort: 7 months of symptoms and their impact, EClinicalMedicine, Volume 38, 2021, 101019.
  8. Ganji Riya, Reddy P. Hemachandra. Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases. Frontiers in Aging Neuroscience 2021.
  9. de Boer E, Petrache I, Goldstein NM, et al. Decreased Fatty Acid Oxidation and Altered Lactate Production during Exercise in Patients with Post-acute COVID-19 Syndrome. Am J Respir Crit Care Med. 2022;205(1):126-129. 
  10. Ziauddeen N, Gurdasani D, O’Hara ME, et al. Characteristics and impact of Long Covid: Findings from an online survey. PLoS One. 2022;17(3):e0264331. Published 2022 Mar 8.
  11. Yong SJ. Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments. Infect Dis (Lond). 2021;53(10):737-754.
  12. Bornstein SR, Voit-Bak K, Donate T, et al. Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Mol Psychiatry. 2022;27(1):34-37.
  13. Tirelli U, Franzini M, Valdenassi L, Pisconti S, Taibi R, Torrisi C, Pandolfi S, Chirumbolo S. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy – preliminary results on 100 patients. Eur Rev Med Pharmacol Sci. 2021 Sep;25(18):5871-5875.
  14. Robbins T, Gonevski M, Clark C, et al. Hyperbaric oxygen therapy for the treatment of long COVID: early evaluation of a highly promising intervention. Clin Med (Lond). 2021;21(6):e629-e632.
  15. Cannellotto, Duarte, Keller, et al Hyperbaric oxygen as an adjuvant treatment for patients with COVID-19 severe hypoxaemia: a randomised controlled trial Emergency Medicine Journal 2022;
  16. Bhaiyat AM, Sasson E, Wang Z, et al. Hyperbaric oxygen treatment for long coronavirus disease-19: a case report. J Med Case Rep. 2022;16(1):80. Published 2022 Feb 15.
  17. Vollbracht C, Kraft K. Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue. Nutrients. 2021;13(4):1154. Published 2021 Mar 31.
  18. Loke XY, Imran SAM, Tye GJ, Wan Kamarul Zaman WS, Nordin F. Immunomodulation and Regenerative Capacity of MSCs for Long-COVID. Int J Mol Sci. 2021;22(22):12421. Published 2021 Nov 17.
  19. U. Tirelli, M. Franzini, L. Valdenassi, S. Pisconti, R. Taibi, C. Torrisi, S. Pandolfi, S. Chirumbolo. Fatigue in post-acute sequelae of SARS-CoV2 (PASC) treated with oxygen-ozone autohemotherapy – preliminary results on 100 patients. Eur Rev Med Pharmacol SciYear: 2021, Vol. 25 – N. 18, Pages: 5871-5875, DOI: 10.26355/eurrev_202109_26809.
  20. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13. PMID: 36639608; PMCID: PMC9839201.
  21. Dabholkar N, Gorantla S, Dubey SK, Alexander A, Taliyan R, Singhvi G. Repurposing methylene blue in the management of COVID-19: Mechanistic aspects and clinical investigations. Biomed Pharmacother. 2021 Oct;142:112023. doi: 10.1016/j.biopha.2021.112023. Epub 2021 Aug 10. PMID: 34399199; PMCID: PMC8352658.
  22. Ana Maria Mihalcea, MD, PhD. Decontaminating The Blood From Synthetic Biology Hydrogel With EDTA Chelation – Live Blood Documentation. April 3 2023.
AMA